In Juno patient deaths, echoes seen of earlier failed company
By Sharon Begley,
STAT
| 07. 08. 2016
Two top executives and dozens of other employees of Juno Therapeutics, the company that on Thursday was forced to halt a clinical trial after three leukemia patients died, are alumni of another biotech company that declared bankruptcy two years ago after disappointing sales of its one product.
And the roots of both Seattle companies’ troubles appear similar to some close observers: a failure to adequately heed the scientific challenges of bringing complicated cancer immunotherapies to market.
“There are echoes here of [the previous company,] Dendreon,” said a health care industry analyst who declined to be named because of concerns it would hurt client relationships. “Both companies were willing to move ahead with something when they had only a superficial, almost cartoonish, understanding of how [the experimental therapy] works at the cellular level. And now three people are dead. … It’s beyond tragic.”
Continue reading on STAT
Image via Pexels
Related Articles
By Anna Collinson and Jo Adnitt, BBC | 08.18.2026
At least 30 children, most of them British, are feared to have been conceived by IVF treatment in northern Cyprus using the wrong sperm or egg donors.
In each case, the parents suspect they did not get the donors they...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
